Anthropic’s big week

Anthropic had two very different headlines this week, and they point in the same direction. One was a reported acquisition of biotech startup Coefficient Bio for about $400 million. The other was the hiring of Amlan Mohanty to run India policy and external affairs as Anthropic deepens its presence in one of its fastest-growing markets. Together, they show the company pushing on two fronts at once: specialized industry use cases and geopolitical expansion. (techcrunch.com) The Coefficient Bio deal is the flashier move. TechCrunch reported on April 3, 2026 that Anthropic bought the stealth startup in a $400 million stock deal, citing prior reporting from The Information and Eric Newcomer, with sources close to the deal confirming that it closed. Coefficient Bio had been using artificial intelligence to make drug discovery and biological research more efficient, and its roughly 10-person team is expected to join Anthropic’s health and life sciences group. (techcrunch.com) That is a small team for a very large price tag, which tells you what Anthropic may have been buying. Coefficient Bio had operated mostly in stealth, with little public detail about its product, but reporting tied its founders Samuel Stanton and Nathan C. Frey to computational drug discovery work at Genentech, suggesting Anthropic wanted highly specialized talent and domain knowledge as much as software. That is an inference, but it fits the structure of the deal as reported. (techcrunch.com) The acquisition also did not come out of nowhere. Anthropic launched Claude Life Sciences in October 2025 as a version of Claude aimed at biopharma work, with use cases spanning scientists, clinical trial coordinators, and regulatory managers. BioSpace reported that companies including Sanofi, Novo Nordisk, and AbbVie were already using Claude in their operations, so Coefficient Bio looks less like a side bet and more like a follow-on move into a market Anthropic had already chosen. (biospace.com) Artificial intelligence and biology have become a natural pairing because biology produces huge, messy datasets and expensive trial-and-error cycles. A model that helps researchers search literature, generate hypotheses, compare molecules, or organize clinical and regulatory workflows can save months of work, even if it never invents a drug on its own. That is why life sciences has become one of the most commercially attractive “vertical” markets for frontier model companies. (biospace.com) Anthropic is not the only company moving this way. BioSpace noted that large biopharma groups are already investing heavily in artificial intelligence, and pointed to Eli Lilly’s recent expansion with Insilico Medicine as another sign of how aggressively drug companies are funding machine-learning-driven research. In that context, Anthropic’s reported $400 million spend looks like a bid to secure a stronger position before the market gets even more crowded. (biospace.com) The India announcement is less expensive-looking, but strategically just as important. On April 9, 2026, The Tech Portal reported that Anthropic appointed Amlan Mohanty to lead India policy and external affairs, with a mandate focused on regulatory engagement and partnerships across government and industry. Mohanty previously worked at Google India in public policy and was also an associate fellow at the Centre for Responsible AI. (thetechportal.com) That hire makes more sense once you look at Anthropic’s own numbers on India. In an October 7, 2025 company announcement, Anthropic said India ranked second globally in consumer usage of Claude, behind only the United States. The company also said a disproportionately large share of Claude usage in India was for technical and programming tasks such as mobile user interface development and web app debugging. (anthropic.com) Anthropic has been building toward a larger India footprint for months. The company said in October 2025 that it planned to open an office in Bengaluru in early 2026, calling it its second office in Asia Pacific after Tokyo. More recently, reporting from January 2026 said Anthropic had hired former Microsoft India chief Irina Ghose as managing director for the country, putting local business leadership in place before adding a dedicated policy chief. (anthropic.com) That sequence matters because India is not just a customer market. It is also a policy battleground, a developer base, and a test case for how global model companies adapt to local regulation, language diversity, and price sensitivity. The Tech Portal reported that Mohanty will help Anthropic engage with policymakers and regulators as India develops its approach to artificial intelligence regulation, data governance, and responsible deployment. (thetechportal.com) Put the two stories together and a pattern emerges. Anthropic is trying to become harder to replace in two ways: by embedding itself in high-value sectors like life sciences, and by building local operating muscle in countries that can shape both demand and regulation. One move is about what Claude can do; the other is about where Anthropic can do it, and under whose rules. (techcrunch.com) There is still uncertainty around the Coefficient Bio deal because much of the reporting says the startup was in stealth and Anthropic has not publicly laid out the exact product roadmap tied to the acquisition. But even with that caveat, this has been a revealing week: Anthropic appears to be spending heavily where artificial intelligence meets biology, while staffing up where artificial intelligence meets government. That is a company preparing for a much broader contest than chatbot market share alone. (techcrunch.com)